NCT05473715: XPAND: aflibercept dosing intervals for macular degeneration

NCT05473715 is XPAND, Bayer's phase IV aflibercept-interval study in neovascular age-related macular degeneration, protocol BAY86-5321/21912. It compared customized proactive intervals with standard treat-and-extend after initial treatment, with a planned noninferiority comparison of change in best-corrected visual acuity at week 36. 1 2

The posted EU results, not just the registration, show four people screened and three randomized/treated: two in the customized group and one in the standard group. None completed the study, and zero participants were analyzed for the primary visual-acuity endpoint. The trial started on April 25, 2023 and ended early on July 11, 2023; the results were posted in July 2024. 2

Accordingly, XPAND produced no usable primary comparison establishing that customized intervals preserved vision as well as the standard approach. That is a specific limitation of this prematurely ended three-person study—not evidence that aflibercept generally fails in wet AMD. Bayer's official page labels the program terminated/withdrawn. 2 3

Sources

1. ClinicalTrials.gov — ClinicalTrials.gov — NCT05473715. Original registration; establishes the exact study identity and registered methods.Original study registration · Original record checked against the registry API. Checked 2026-10-10. Registration and current registry fields do not by themselves establish efficacy. Historical details in the article retain their stated date. Supplied note: ClinicalTrials.gov — NCT05473715. Original registration; establishes the exact study identity and registered methods.

2. EU Clinical Trials Register — EU Clinical Trials Register — EudraCT 2022-000690-73, posted results for XPAND. Primary sponsor-submitted results, including participant flow and the zero-patient primary analysis.Cited supporting source · Link and description preserved from supplied research. Checked in supplied research dated 2026-10-10. Source description comes from supplied research; underlying page was not independently re-read for this update.

3. Bayer — Bayer — Study 21912, official sponsor trial page. Supports protocol identity and termination status.Cited supporting source · Link and description preserved from supplied research. Checked in supplied research dated 2026-10-10. Source description comes from supplied research; underlying page was not independently re-read for this update.